Adult Malignant Glioma Therapeutics Market Forecast 2024-2033: Growth Rate, Drivers, And Trends

Spread the love

The Adult Malignant Glioma Therapeutics Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Adult Malignant Glioma Therapeutics Market:
https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

According to The Business Research Company’s Adult Malignant Glioma Therapeutics Global Market Report 2024, The adult malignant glioma therapeutics market size has grown rapidly in recent years. It will grow from $2.03 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to increased incidence rates, patient advocacy initiatives, personalized medicine approaches..

The adult malignant glioma therapeutics market size is expected to see strong growth in the next few years. It will grow to $3.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to immunotherapy advancements, targeted therapies, biomarker discoveries, liquid biopsy applications, expanded access programs.. Major trends in the forecast period include patient-centric drug development, fast-track and breakthrough designation, advances in drug delivery systems, collaborative research initiative, integration of artificial intelligence..

The growing cases of brain tumors are expected to drive the adult malignant glioma therapeutics market growth. A brain tumor is an abnormal mass of tissue in which the normal systems that regulate cells appear not to affect the uncontrollable growth and multiplication of the cells. Adult malignant glioma is a type of brain tumor made up of cells that grow abnormally and uncontrollably. Adult malignant glioma treatment treats brain tumors by combining surgery, radiation therapy, and chemotherapy. For instance, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of brain and nervous system cancer cases increased to 24,810 in 2023, reflecting a growth of 3.85% from 23,890 in 2020. Therefore, the growing cases of brain tumors are driving the adult malignant glioma therapeutics market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

The adult malignant glioma therapeutics market covered in this report is segmented –

1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types
2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies
3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

Major companies operating in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to provide reliable customer service. A small-molecule targeted degrader is a drug that uses small molecules to induce the degradation of specific proteins by targeting the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a Sweden-based precision oncology company, received orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17 to treat glioblastoma (GBM). It is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST that has been implicated in the pathogenesis of various cancers, including GBM. BEA-17 works by degrading LSD1 and CoREST, which leads to the reactivation of tumor suppressor genes and the inhibition of cancer cell growth.

The adult malignant glioma therapeutics market report table of contents includes:

1. Executive Summary
2.Adult Malignant Glioma Therapeutics  Market Characteristics
3.Adult Malignant Glioma Therapeutics  Market Trends And Strategies
4.Adult Malignant Glioma Therapeutics  Market analysis
5.Adult Malignant Glioma Therapeutics  Market Size And Growth
6.Adult Malignant Glioma Therapeutics  Segmentation
7.Adult Malignant Glioma Therapeutics  Regional And Country Analysis
.
.
.
27.Adult Malignant Glioma Therapeutics  Competitive Landscape And Company Profiles
28.Adult Malignant Glioma Therapeutics  Key Mergers And Acquisitions
29.Adult Malignant Glioma Therapeutics  Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

  • Johnson & Johnson Private Limited
  • Pfizer Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche Ltd.

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model


Spread the love

About Top PR News

TopPRnews Leads Drives Search Engine Visibility For Your Press Release Content. Our Global Network Reaches Important Contacts, Media Partners And Websites And Journalists. Happy Postings! If You Have Any Queries Please Contact Official Mail At [[email protected]}

View all posts by Top PR News →